Interferon-β lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-β gene transfer to human tumor cells

Villaverde, Marcela Solange; Gil-Cardeza, María L.; Glikin, Gerardo C.; Finocchiaro, Liliana M.E.

doi:10.1038/cgt.2012.19

Cited by 9 publications

(17 citation statements)

References 38 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study showed that cytotoxic effects (e.g. apoptosis, necrosis, and early senescence) of human IFNβ gene lipofection showed the same or a superior effect to that of high doses of the exogenously applied recombinant IFNβ protein [76]. Based on these findings, the researchers also found that fIFN-ω lipofection and expression is equal to or more effective than rFIFN-ω protein at suppressing cell growth by inducing ROS generation, mitochondrial potential disruption and calcium uptake [77].…”

Section: Biological Activities Of Type I Ifnsmentioning

confidence: 99%

Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection

Gong

Zhao

et al. 2018

Cell Physiol Biochem

130

111

View full text Add to dashboard Cite

The interferons (IFNs) are a primary defense against pathogens because of the strong antiviral activities they induce. IFNs can be classified into three groups: type I, type II and type III, according to their genetic, structural, and functional characteristics and their receptors on the cell surface. The type I IFNs are the largest group and include IFN-α, IFN-β, IFN-ε, IFN-ω, IFN-κ, IFN-δ, IFN-τ and IFN-ζ. The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications. Therefore, in this review, we summarize the recent progress in the study of the biological activities of all the type I IFN classes and their potential applications in the treatment of infections with immunodeficiency virus, hepatitis viruses, and influenza viruses.

show abstract

Section: Biological Activities Of Type I Ifnsmentioning

confidence: 99%

Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection

Gong

Zhao

et al. 2018

Cell Physiol Biochem

130

111

View full text Add to dashboard Cite

show abstract

“…Thus, rFeIFN-ω may be used as a therapeutic agent in feline and canine mammary carcinomas. There is evidence showing that gene transfer would allow one to take advantage of the beneficial effects of type I IFNs without their undesirable side effects [52]. For instance, HuIFNβ gene lipofection produces an equal or even superior effect than that of high doses of exogenously applied HuIFNβ protein.…”

Section: Anti-proliferation and Antitumor Activity Of Ifn-ω In Bench mentioning

confidence: 99%

“…For instance, HuIFNβ gene lipofection produces an equal or even superior effect than that of high doses of exogenously applied HuIFNβ protein. Recently, a study conducted by Villaverde et al [52] demonstrated that felines FeIFN-ω gene lipofection exhibited an equal or higher cytotoxic effect than rFeIFN-ω. This kind of effect was due to the induction of reactive oxygen species generation, mitochondrial membrane potential disruption, and calcium uptake, indicating that fFeIFN-ω lipofection is an alternative approach for treating both sensitive and resistant phenotypes with an equal or superior outcome and with fewer adverse effects than recombinant fFeIFN-ω therapy [52].…”

Section: Anti-proliferation and Antitumor Activity Of Ifn-ω In Bench mentioning

confidence: 99%

“…Recently, a study conducted by Villaverde et al [52] demonstrated that felines FeIFN-ω gene lipofection exhibited an equal or higher cytotoxic effect than rFeIFN-ω. This kind of effect was due to the induction of reactive oxygen species generation, mitochondrial membrane potential disruption, and calcium uptake, indicating that fFeIFN-ω lipofection is an alternative approach for treating both sensitive and resistant phenotypes with an equal or superior outcome and with fewer adverse effects than recombinant fFeIFN-ω therapy [52]. Similarly, injecting the gene encoding interferon ω1 via the tail vein into mice bearing a Hep-A-22 liver tumor via liposomal gene delivery also significantly decreased tumor weights [53].…”

Section: Anti-proliferation and Antitumor Activity Of Ifn-ω In Bench mentioning

confidence: 99%

See 1 more Smart Citation

Interferon-omega: Current status in clinical applications

Zhao

Shao

et al. 2017

International Immunopharmacology

View full text Add to dashboard Cite

Since 1985, interferon (IFN)-ω, a type I IFN, has been identified in many animals, but not canines and mice. It has been demonstrated to have antiviral, anti-proliferation, and antitumor activities that are similar to those of IFN-α. To date, IFN-ω has been explored as a treatment option for some diseases or viral infections in humans and other animals. Studies have revealed that human IFN-ω displays antitumor activities in some models of human cancer cells and that it can be used to diagnose some diseases. While recombinant feline IFN-ω has been licensed in several countries for treating canine parvovirus, feline leukemia virus, and feline immunodeficiency virus infections, it also exhibits a certain efficacy when used to treat other viral infections or diseases. This review examines the known biological activity of IFN-ω and its clinical applications. We expect that the information provided in this review will stimulate further studies of IFN-ω as a therapeutic agent.

show abstract

“…These results are in agreement with the fact that the great bystander effect of the hIFNb gene lipofection involves the production of reactive oxygen species, simultaneous with a mitochondrial potential decrease in both cell lines. 39 The combination antineoplastic drug/hIFNb gene in the chemotherapy-sensitive cells (monolayers of EW7) displayed only additive or counteractive effects. This suggests that, when cells do not exhibit resistance, the cytotoxic mechanisms triggered by hIFNb gene lipofection may be saturating the signaling pathways.…”

Section: Discussionmentioning

confidence: 99%

Interferon-β lipofection I. Increased efficacy of chemotherapeutic drugs on human tumor cells derived monolayers and spheroids

et al. 2012

Self Cite

View full text Add to dashboard Cite

We evaluated the effect of hIFNb gene transfer alone or in combination with different antineoplastic drugs commonly used in cancer treatment. Five human tumor-derived cell lines were cultured as monolayers and spheroids. Four cell lines (Ewing sarcomas EW7 and COH, melanoma M8 and mammary carcinoma MCF-7) were sensitive to hIFNb gene lipofection. Although this effect appeared in both culture configurations, spheroids showed a relative multicellular resistance (insensitive colon carcinoma HT-29 excluded). EW7 and M8 hIFNb-expressing cells were exposed to different concentrations of bleomycin, bortezomib, carboplatin, doxorubicin, etoposide, methotrexate, paclitaxel and vincristine in both configuration models. In chemotherapy-sensitive EW7 monolayers, the combination of hIFNb gene and antineoplastic drugs displayed only additive or counteractive (methotrexate) effects, suggesting that cytotoxic mechanisms triggered by hIFNb gene lipofection could be saturating the signaling pathways. Conversely, in chemotherapy-resistant EW7 spheroids or M8 cells, the combination of hIFNb with drugs that mainly operate at the genotoxic level (doxorubicin, methotrexate and paclitaxel) presented only additive effects. However, drugs that also increase pro-oxidant species can complement the antitumor efficacy of the hIFNb gene and clearly caused potentiated effects (bleomycin, bortezomib, carboplatin, etoposide and vincristine). The great bystander effect induced by hIFNb gene lipofection could be among the main causes of its effectiveness, because only 1 or 2% of EW7 or M8 hIFNb-expressing cells killed more than 60 or 80% of cell population, respectively.

show abstract

Interferon-β lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-β gene transfer to human tumor cells

Cited by 9 publications

References 38 publications

Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection

Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection

Interferon-omega: Current status in clinical applications

Interferon-β lipofection I. Increased efficacy of chemotherapeutic drugs on human tumor cells derived monolayers and spheroids

Contact Info

Product

Resources

About